Share Name Share Symbol Market Type Share ISIN Share Description
Core Vct I LSE:CR. London Ordinary Share GB00B03FH337 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 72.00p 0.00p 0.00p - - - 0 06:40:20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - - 7.87

Core Vct I Share Discussion Threads

Showing 800776 to 800798 of 800800 messages
Chat Pages: 32032  32031  32030  32029  32028  32027  32026  32025  32024  32023  32022  32021  Older
DateSubjectAuthorDiscuss
19/1/2018
11:06
MYN - Mayan Energy - Golden Cross DMAs moving closer together again as shown below on the last 5 trading days. Looks like the 25 DMA will cross on Monday and the 50 DMA will go though on wednesday at present. Of course the share price would need to be around 0.8p for this to play out.
brasso3
19/1/2018
09:19
Tim McCarthy (ImmuPharma Chairman) 18/1/2018 6 min. 45 sec. hTTps://www.youtube.com/watch?v=zrmthFUsvoY "I am really excited that in a relatively short period of time, we could have a drug [Lupuzor] on the market which would benefit literally millions of patients across the world for a condition for which they havn't had an effective treatment ever... ...to be a relatively small UK company, sitting here as we do with this late stage product, owning 100% of it, from a commercial perspective that's really exciting as well because this is potentially a multi-billion dollar drug...this is definately going to be a product which will sell in the multi-billion dollars per year... ...we [IMM] are still only valued at £200 - £250 million. In pharmaceutical terms and the prospect of this drug, that is absolutely still very tiny when you consider the potential of this drug...There are a number of discussions going on...so its exciting on a number of fronts." Another interview on same day: hTTps://www.directorstalkinterviews.com/interview-immupharma-plc-extension-study-request-patients/412744093
hottingup
19/1/2018
09:08
TYM (1.65-1.7) Looking tempting at this level.
yawn3
19/1/2018
09:04
AERO Drifting again
yawn3
19/1/2018
08:40
DKE An easy 5 bagger short term ino. Can buy under 0.45 yet broker target price 2.3p
market master
19/1/2018
07:42
PXOG today's bagger and lots more to come over the rest of 2018!
blueblood
18/1/2018
22:08
Huge news out on the ASX for PXOG and UOG. http://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&idsId=01942342 PXOG have a slightly lower % than UOG (17% vs 20%) but around half the market cap. Both should do well in the morning :)
on target
18/1/2018
11:23
AERO Drifting further.
yawn3
18/1/2018
10:24
BNR Look poised
yawn3
18/1/2018
08:35
SIS Only about 60-70M shares in issue!
garbut
18/1/2018
08:28
RRR AlignResearch "Ref Red Rock Res #RRR with the hoped for Jupiter Mines receipt we believe a special divi payment of in excess of the current stock price would be appropriate. Would provide a clear route to proper value of the stock & silence misplaced critics."
yawn3
18/1/2018
08:04
RRR AlignResearch "Re Red Rock Resources, Note that we value the Steelmin 22% rump equity stake RRR will retain (and on a fully diluted basis too) at @ 1.4p per share alone. Reiterating our Conviction Buy call here -
yawn3
18/1/2018
08:04
#DKE ticked up from the start with flurry of buys. Should test .50's today
market master
18/1/2018
07:19
RRR Steelmin Update Andrew Bell, Chairman of Red Rock comments: "We are delighted to see that Steelmin appears to be on track both to repay its facility from us before the due date and to begin ferrosilicon production within the Q1 2018 schedule. On the basis that the Agreement, which is subject to some rights of withdrawal by the lender, completes, and on the basis of current exchange rates, we would be left with a net positive balance of some £1.8m on the back to back facility after repayment of all amounts due to and from Red Rock. We would also have a 21-22% shareholding in Steelmin. Seven months after the initial investment by us in Steelmin, this would be a positive outcome. As ferrosilicon prices are strengthening, it is important that Steelmin start production soon, and we hope before long to see planning for the refurbishment of the second furnace."
yawn3
17/1/2018
14:43
MYN..... tidy 2 17 Jan '18 - 13:48 - 1985 of 1986 0 2 0 RT AlignResearch "Ref Mayan Energy #MYN - we have spoken with Chairman charlieawood and have had confirmed that speculation of an imminent placing in the stock is wholly misplaced. We are taking advantage of weakness in attempting to add to our position. #alignment TexasEddieG"
nicosevos
17/1/2018
14:42
MYN..... tidy 2 17 Jan '18 - 13:48 - 1985 of 1986 0 2 0 RT AlignResearch "Ref Mayan Energy #MYN - we have spoken with Chairman charlieawood and have had confirmed that speculation of an imminent placing in the stock is wholly misplaced. We are taking advantage of weakness in attempting to add to our position. #alignment TexasEddieG"
nicosevos
17/1/2018
13:31
large trade (buy?) on mka today (625k shares = £72k)
andrbea
17/1/2018
10:38
Shares Magazine Small caps poised for big news in 2018: We look at 19 stocks primed to deliver major events in their career 21/12/2017 hTTps://www.sharesmagazine.co.uk/article/small-caps-poised-for-big-news-in-2018 "Drug developer ImmuPharma (IMM) is expecting Phase III results in the first quarter of 2018 for lupus treatment Lupuzor. Analysts speculate the drug could hit multi-billion dollar annual sales if the tests are successful and the drug gets approved by the regulators." This promising small-cap stock could be a millionaire maker in 2018 Paul Summers Tue. 26/12/2017 hTTps://www.fool.co.uk/investing/2017/12/26/this-promising-small-cap-stock-could-be-a-millionaire-maker-in-2018/ The suggestion that a single stock could lead some investors to become millionaires next year may sound fanciful but I think this is quite possible if events work out for small-cap drug discovery and development firm ImmuPharma (LSE: IMM). Let me explain. Blockbuster potential Over the last three months, shares in the AIM-listed company have climbed more than 200% in value as anticipation grows over the outcome of a Phase III clinical trial for Lupuzor — its 100%-owned potential treatment for Lupus. Approximately five million people are believed to suffer from the chronic and potentially life-threatening autoimmune disease that can be a notoriously difficult to treat. In the last 50 years, only one therapy — GlaxoSmithKline‘s Benlysta — has been approved for use, despite its questionable efficacy and serious side-effects. In 2015, the drug achieved sales of over $400m. By 2020, this figure is expected to rise to $1bn. Positively, data from Lupuzor’s Phase IIb trial indicated that ImmuPharma’s treatment — which modulates rather than blocks the immune system — was both effective and safe. Moreover, the effectiveness of Lupuzor increased even after the three-month trial’s conclusion. Investors will be hoping that the 52-week, randomised and double-blinded study currently in progress (involving patients in the US, Europe and Mauritius) yields similar results. In its most recent update on 21 December, the company revealed that all 200 participants had now received the full 12-month dosage and that the “robust safety record” shown in earlier trials continues to be seen. According to Chairman Tim McCarthy, the company looks forward “with continued confidence” to reporting on top-line results in Q1 of next year. In the event of a positive outcome, ImmuPharma will then seek to exploit its Fast Track designation and push for approval from the Food and Drug Administration (FDA). Once received, the company would then be free to seek out a global licensing deal for taking Lupuzor to market or — perhaps more likely — consider takeover bids by deep-pocketed pharmaceutical giants at a price befitting its blockbuster potential. Given the suggestion that it could be used in the treatment of other diseases, the price could easily be in the billions of pounds. Right now, ImmuPharma’s market cap is a little over £200m.
hottingup
17/1/2018
08:18
DEMG! Cannot buy 50 quids worth after that RNS!! Deltex Medical!
garbut
17/1/2018
08:13
#DKE very tight spread with the bid higher than the offer: Bid 0.41 Ask 0.409 After a flurry of large buys yesterday around 9 million buys
market master
16/1/2018
07:47
" With this change, our sum of the parts valuation for Mayan Energy has increased to £65.45 million and which suggests a price of 5.21p per shares on a fully diluted basis per the table below:" Http://www.alignresearch.co.uk/oil/1911/
brasso3
15/1/2018
17:47
Golden Cross about to form on the MYN chart. I reckon we are talking 3 - 5 trading sessions before that happens. :)
brasso3
15/1/2018
16:29
PREM - firming into the close. f
fillipe
Chat Pages: 32032  32031  32030  32029  32028  32027  32026  32025  32024  32023  32022  32021  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20180119 11:41:25